Probiotics and magnesium orotate for the treatment of major depressive disorder: a randomised double blind controlled trial.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
06 Sep 2024
06 Sep 2024
Historique:
received:
09
02
2024
accepted:
23
08
2024
medline:
7
9
2024
pubmed:
7
9
2024
entrez:
6
9
2024
Statut:
epublish
Résumé
Following on from our pilot studies, this study aimed to test the efficacy of a combination of probiotics (Lactobacillus acidophilus, Bifidobacterium bifidum, Streptococcus thermophilus), magnesium orotate and coenzyme 10 for the treatment of major depressive disorder (MDD) through a double-blind placebo controlled clinical trial. The participants were 120 adults diagnosed with MDD randomised to daily oral administration, over 8 weeks, of either the intervention or placebo, with a 16-week follow-up period. Intent-to-treat analysis found a significantly lower frequency of the presence of a major depressive episode in the intervention group compared with placebo at the end of the 8-week treatment phase, with no difference between the two conditions at 8-week follow-up. Both the categorical and continuous measure of depressive symptoms showed a significant difference between the two conditions at 4 weeks, but not 8 and 16 weeks. The secondary end-point was demonstrated with an overall reduction in self-rated symptoms of anxiety and stress in the active treatment group compared with placebo. These findings suggest that the combination of probiotics, magnesium orotate and coenzyme 10 may be an effective treatment of MDD over an 8-week period.
Identifiants
pubmed: 39242786
doi: 10.1038/s41598-024-71093-z
pii: 10.1038/s41598-024-71093-z
doi:
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
20841Informations de copyright
© 2024. The Author(s).
Références
James, S. L. et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet 392(10159), 1789–1858 (2018).
doi: 10.1016/S0140-6736(18)32279-7
Lim, G. Y. et al. Prevalence of depression in the community from 30 countries between 1994 and 2014. Sci. Rep. 8, 2861–2961 (2018).
doi: 10.1038/s41598-018-21243-x
pubmed: 29434331
pmcid: 5809481
Hasin, D. S. et al. Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States. JAMA Psychiatry 75, 336–346 (2018).
doi: 10.1001/jamapsychiatry.2017.4602
pubmed: 29450462
pmcid: 5875313
Santomauro, D. F. et al. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet 398(10312), 1700–1712 (2021).
doi: 10.1016/S0140-6736(21)02143-7
Malhi, G. S. et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Austr. N. Zeal. J. Psychiatry 49(12), 1087–1206 (2015).
doi: 10.1177/0004867415617657
Kendrick, T. et al. Management of depression in adults: Summary of updated NICE guidance. BMJ 20, 378 (2022).
Gartlehner, G. et al. Pharmacological and non-pharmacological treatments for major depressive disorder: Review of systematic reviews. BMJ Open 7(6), e014912 (2017).
doi: 10.1136/bmjopen-2016-014912
pubmed: 28615268
pmcid: 5623437
Gartlehner, G. et al. Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: An updated meta-analysis. Ann. Intern. Med. 155(11), 772–785 (2011).
doi: 10.7326/0003-4819-155-11-201112060-00009
pubmed: 22147715
Cuijpers, P. et al. The effects of psychotherapies for major depression in adults on remission, recovery and improvement: A meta-analysis. J. Affect. Disord. 159, 118–126. https://doi.org/10.1016/j.jad.2014.02.026 (2014).
doi: 10.1016/j.jad.2014.02.026
pubmed: 24679399
Cascade, E., Kalali, A. H. & Kennedy, S. H. Real-world data on SSRI antidepressant side effects. Psychiatry (Edgmont) 6(2), 16 (2009).
pubmed: 19724743
Musazadeh, V. et al. Probiotics as an effective therapeutic approach in alleviating depression symptoms: An umbrella meta-analysis. Crit. Rev. Food Sci. Nutr. 63(26), 8292–8300 (2023).
doi: 10.1080/10408398.2022.2051164
pubmed: 35348020
Sanada, K. et al. Gut microbiota and major depressive disorder: A systematic review and meta-analysis. J. Affect. Disord. 266, 1–3 (2020).
doi: 10.1016/j.jad.2020.01.102
pubmed: 32056863
Ng, Q. X. et al. Effect of probiotic supplementation on gut microbiota in patients with major depressive disorders: A systematic review. Nutrients 15(6), 1351 (2023).
doi: 10.3390/nu15061351
pubmed: 36986088
pmcid: 10052013
Liu, R. T., Walsh, R. F. L. & Sheehan, A. E. Prebiotics and probiotics for depression and anxiety: A systematic review and meta-analysis of randomized controlled trials. BMC Psychiatry 23(1), 1–11. https://doi.org/10.1186/s12888-023-04685-w (2023).
doi: 10.1186/s12888-023-04685-w
Li, J. et al. The effect and safety of probiotics on depression: A systematic review and meta-analysis of randomized controlled trials. Eur. J. Nutr. 62(2), 1–19. https://doi.org/10.1007/s00394-022-02910-5 (2023).
doi: 10.1007/s00394-022-02910-5
Liu, L. et al. Gut microbiota and its metabolites in depression: from pathogenesis to treatment. EBioMedicine 90, 104527 (2023).
doi: 10.1016/j.ebiom.2023.104527
pubmed: 36963238
pmcid: 10051028
Bambling, M., Edwards, S. C., Hall, S. & Vitetta, L. A combination of probiotics and magnesium orotate attenuate depression in a small SSRI resistant cohort: An intestinal anti-inflammatory response is suggested. Inflammopharmacology 25(2), 271–274 (2017).
doi: 10.1007/s10787-017-0311-x
pubmed: 28155119
Schiopu, C. et al. Magnesium orotate and the microbiome–gut–brain axis modulation: New approaches in psychological comorbidities of gastrointestinal functional disorders. Nutrients 14(8), 1567 (2022).
doi: 10.3390/nu14081567
pubmed: 35458129
pmcid: 9029938
Maes, M. et al. Lower plasma Coenzyme Q 10 in depression: A marker for treatment resistance and chronic fatigue in depression and a risk factor to cardiovascular disorder in that illness. Neuroendocrinol. Lett. 30(4), 462–469 (2009).
pubmed: 20010493
Majmasanaye, M., Mehrpooya, M., Amiri, H. & Eshraghi, A. Discovering the potential value of coenzyme Q10 as an adjuvant treatment in patients with depression. J. Clin. Psychopharmacol. 44(3), 232–239 (2024).
doi: 10.1097/JCP.0000000000001845
pubmed: 38684047
First, M.B., Williams, J.B., Karg, R.S., Spitzer, R.L. American Psychiatric Association. Arlington. VA, American Psychiatric Association. (2015).
Osório, F. L. et al. Clinical validity and intrarater and test–retest reliability of the Structured Clinical Interview for DSM-5–Clinician Version (SCID-5-CV). Psychiatry Clin. Neurosci. 73(12), 754–760 (2019).
doi: 10.1111/pcn.12931
pubmed: 31490607
Beck, A. T., Steer, R. A. & Brown, G. Beck Depression Inventory–II [Internet]. PsycTESTS Dataset (American Psychological Association (APA), 1996). https://doi.org/10.1037/t00742-000 .
doi: 10.1037/t00742-000
Wang, Y. P. & Gorenstein, C. Psychometric properties of the Beck Depression Inventory-II: A comprehensive review. Braz. J. Psychiatry 35(4), 416–431 (2013).
doi: 10.1590/1516-4446-2012-1048
pubmed: 24402217
Spitzer, R. L., Kroenke, K., Williams, J. B. W. & Löwe, B. A brief measure for assessing generalized anxiety disorder. Arch. Intern. Med. [Internet] 166(10), 1092. https://doi.org/10.1001/archinte.166.10.1092 (2006).
doi: 10.1001/archinte.166.10.1092
pubmed: 16717171
Cohen, S., Kamarck, T. & Mermelstein, R. A global measure of perceived stress. J. Health Soc. Behav. [Internet] 24(4), 385. https://doi.org/10.2307/2136404 (1983).
doi: 10.2307/2136404
pubmed: 6668417
Moran, P. et al. Standardised Assessment of Personality—Abbreviated Scale (SAPAS): Preliminary validation of a brief screen for personality disorder. Br. J. Psychiatry [Internet] 183(3), 228–32. https://doi.org/10.1192/bjp.183.3.228 (2003).
doi: 10.1192/bjp.183.3.228
pubmed: 12948996
Mörkl, S., Butler, M. I., Holl, A., Cryan, J. F. & Dinan, T. G. Probiotics and their impact on the gut-brain axis with a focus on mental health: A systematic review and meta-analysis of randomized controlled trials from 2014 to 2023. Microorganisms 11(4), 1–20. https://doi.org/10.3390/microorganisms11040085 (2023).
doi: 10.3390/microorganisms11040085
Nikolova, Y. S., Worry, K. & Hayes, R. Effects of probiotics on depressive symptoms and emotional cognition: A randomized controlled trial. JAMA Psychiatry 80(7), 677–685. https://doi.org/10.1001/jamapsychiatry.2023.1817 (2023).
doi: 10.1001/jamapsychiatry.2023.1817
Alli, S. R. et al. The gut microbiome in depression and potential benefit of prebiotics, probiotics and synbiotics: A systematic review of clinical trials and observational studies. Int. J. Mol. Sci. 23(9), 4494 (2022).
doi: 10.3390/ijms23094494
pubmed: 35562885
pmcid: 9101152
Bambling, M., Edwards, S. C., Coulson, S. & Vitetta, L. S-adenosylmethionine (SAMe) and Magnesium Orotate as adjunctives to SSRIs in sub-optimal treatment response of depression in adults; a pilot study. Adv. Integr. Med. 2, 56–62 (2015).
doi: 10.1016/j.aimed.2015.04.003
You, S. et al. The promotion mechanism of prebiotics for probiotics: A review. Front. Nutr. 9, 1000517 (2022).
doi: 10.3389/fnut.2022.1000517
pubmed: 36276830
pmcid: 9581195
Vitetta, L., Bambling, M. & Strodl, E. Probiotics and commensal bacteria metabolites trigger epigenetic changes in the gut and influence beneficial mood dispositions. Microorganisms 11(5), 1334 (2023).
doi: 10.3390/microorganisms11051334
pubmed: 37317308
pmcid: 10221035
Ritchie, G. et al. An exploratory study of the gut microbiota in major depression with anxious distress. J. Affect. Disord. 320, 595–604 (2023).
doi: 10.1016/j.jad.2022.10.001
pubmed: 36209779
Rief, W. et al. Meta-analysis of the placebo response in antidepressant trials. J. Affect. Disord. 118(1–3), 1–8 (2009).
doi: 10.1016/j.jad.2009.01.029
pubmed: 19246102
Jones, B. D. et al. Magnitude of the placebo response across treatment modalities used for treatment-resistant depression in adults: A systematic review and meta-analysis. JAMA Netw. Open 4(9), e2125531 (2021).
doi: 10.1001/jamanetworkopen.2021.25531
pubmed: 34559231
pmcid: 8463940